Immune Design Corp. (IMDZ) Major Shareholder Acquires $279,000.00 in Stock

Immune Design Corp. (NASDAQ:IMDZ) major shareholder Leo Guthart bought 60,000 shares of Immune Design Corp. stock in a transaction on Tuesday, October 24th. The shares were purchased at an average cost of $4.65 per share, with a total value of $279,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Leo Guthart also recently made the following trade(s):

  • On Friday, October 27th, Leo Guthart bought 2,439,000 shares of Immune Design Corp. stock. The shares were purchased at an average cost of $4.10 per share, with a total value of $9,999,900.00.
  • On Thursday, October 19th, Leo Guthart bought 10,000 shares of Immune Design Corp. stock. The shares were purchased at an average cost of $6.09 per share, with a total value of $60,900.00.
  • On Monday, September 18th, Leo Guthart bought 10,000 shares of Immune Design Corp. stock. The shares were purchased at an average cost of $9.70 per share, with a total value of $97,000.00.

Shares of Immune Design Corp. (NASDAQ IMDZ) traded up $0.40 during trading on Friday, reaching $4.95. The company had a trading volume of 911,300 shares, compared to its average volume of 285,005. Immune Design Corp. has a 52 week low of $3.78 and a 52 week high of $13.05.

Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.11. The company had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.62 million. Immune Design Corp. had a negative return on equity of 68.69% and a negative net margin of 619.62%. analysts anticipate that Immune Design Corp. will post -1.89 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/11/immune-design-corp-imdz-major-shareholder-buys-279000-00-in-stock.html.

A number of equities analysts have commented on IMDZ shares. Wells Fargo & Company cut Immune Design Corp. from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. ValuEngine cut Immune Design Corp. from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. Zacks Investment Research raised Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Tuesday, July 18th. Royal Bank of Canada assumed coverage on Immune Design Corp. in a report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price target for the company. Finally, BidaskClub cut Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Immune Design Corp. has an average rating of “Hold” and a consensus target price of $13.19.

A number of institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its position in Immune Design Corp. by 9.3% in the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 1,600 shares during the period. FMR LLC grew its position in Immune Design Corp. by 0.4% in the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock worth $3,027,000 after acquiring an additional 1,699 shares during the period. California State Teachers Retirement System grew its position in Immune Design Corp. by 8.3% in the second quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 2,300 shares during the period. Trexquant Investment LP grew its position in Immune Design Corp. by 15.5% in the second quarter. Trexquant Investment LP now owns 31,152 shares of the biotechnology company’s stock worth $304,000 after acquiring an additional 4,174 shares during the period. Finally, Teachers Advisors LLC grew its position in Immune Design Corp. by 23.0% in the second quarter. Teachers Advisors LLC now owns 27,691 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 5,181 shares during the period. Institutional investors own 51.76% of the company’s stock.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply